ABSTRACT-We investigated the subtype of a-adrenoceptors participating in central noradrenergic inhibi tion of gastric motility in urethane-anesthetized rats. Noradrenaline at 10 nmole administered intracisternal ly (i.c.) significantly decreased gastric motility. Yohimbine at 10 nmole, i.c., but not the same dose of prazosin, abolished this noradrenaline-induced decrease in gastric motility. Clonidine at 10 nmole, i.c., but not phenylephrine at 20 nmole, significantly decreased gastric motility. These results suggest that a2 adrenoceptor-mediated mechanisms in the brain stem are involved in noradrenergic inhibitory regulation of gastric motility.
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Several lines of evidence indicate that central a2 adrenoceptors mediate inhibition of visceral functions such as gastric acid secretion (1, 2) and small intestinal motility (3, 4) . We recently reported that activation of a adrenoceptors in the brain stem with noradrenaline in hibited gastric motility (5). Our present study was done to determine the subtype of a-adrenoceptors mediating the central noradrenergic inhibition of gastric motility.
Male Wistar rats weighing 350-400 g were used. Prior to each experiment, food was withheld for 24 hr but water was provided. Animals were anesthetized with ure thane (1.25 g/kg, i.p.). Gastric motility was measured with the previously reported method (6) . In brief, a flaccid intragastric balloon was inserted into the stomach through an incision of the fundus. Changes in intragastric pressure induced by gastric contraction were measured by a pressure transducer connected to the balloon and a pen writing recorder. The mean amplitude of monitored waves was calculated for consecutive 2-min periods and was taken to indicate gastric motility.
Test substances were dissolved in artificial cerebro spinal fluid (CSF), the composition of which was 7.3 mg NaCl, 1.9 mg NaHCO3, 0.3 mg MgSO4, 0.2 mg CaC12 and 0.2 mg NaH2PO4 in 1 ml of deionized water; i.e., a slight modification of the composition described by Falcon et al. (7) . The volume of test substances for central administration was 10 pl.
Student's t-test was used for comparison between two groups and Duncan's multiple range test was used for mul tiple comparison. P values of less than 5 % were consi dered to indicate a statistically significant difference. When the intragastric pressure applied was about 100 mmH2O, spontaneous and rhythmic contractions of the stomach with an amplitude of 85.2±6.1 mmH2O (n=37) were observed. Because of relatively large individual variations, the results obtained were, unless otherwise described, expressed as percent changes to the basal value (the basal value being the mean of three values from the triplicate 2-min periods preceding administration of test substances).
In the first series of experiments, we used prazosin and yohimbine as the a, and a2-antagonist, respectively. Noradrenaline at 10 nmole administered i.c. significantly decreased gastric motility (Fig. 1 ). Yohimbine at 10 nmole, i.c., but not the same dose of prazosin, inhibited this noradrenaline-induced decrease in gastric motility (Table 1) . It is, therefore, evident that al-adrenoceptors are not involved in noradrenaline-induced inhibition of gastric motility. However, yohimbine at 10 nmole alone significantly increased gastric motility (Table 1) . This in crease is not due to disinhibition of central noradrenergic mechanisms, since pretreatment of animals with reserpine (2 mg/kg, i.p. for 24 hr) did not attenuate it ( Table 1) . The dose of reserpine used in this experiment was sufficient to decrease the noradrenaline content in the rat brain to less than approximately 2010 of that in the non reserpinized animals (8) . These results suggest that yohim bine has a central stimulatory effect on gastric motility. Regarding gastric acid secretion, Bernardini et al. (9) reported that the secretory effect of yohimbine seemed to be mainly attributable to its central stimulatory action. Both rauwolscine and idazoxane alone, used as other an tagonists of a2-adrenoceptor, also increased gastric motil ity (Table 1) . Thus, we could not confirm whether or not yohimbine antagonized the noradrenaline-induced inhi bition of gastric motility by its a2-adrenoceptor blocking action. Then, in the second series of experiments, we used clonidine and phenylephrine as a, and a2-agonists, respectively.
Clonidine at 10 nmole, i.c. significantly decreased gas tric motility, but phenylephrine at 20 nmole, i.c. had no effect (Table 1) . These results suggest that central noradrenergic inhibition of gastric motility is probably mediated by activation of a2-adrenoceptors in the brain stem. 
